Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 11 sales; 273 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $3.59B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.32M in total
- 11
- 13F holdersQ2 2026, +4 vs. previous quarter
- 273
- 13F valueReported value at the end of Q2 2026
- $3.45B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $376.1M
- +91.3% year over year
- Net income, FY2025
- -$16.1M
- No comparable prior period
- Free cash flow, FY2025
- -$6.31M
- No comparable prior period
- Revenue, Q3 FY2026
- $143.9M
- +45.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $16.1M (4.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 18.2M
- Shares sold short
- Change
- −2.33M
- −11.4% vs. previous
- Days to cover
- 7.58
- At average daily volume
Superinvestors holding ARQT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ARQT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Arcutis Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)6:38 PM ET | Nov 2-4 | 2 days | Matsuda MasaruEVP, Chief Legal Officer | SSale | −41.2K | $34.24 | −$1.41M | −27.0%111.3K after | 2 lots10b5-1 |
| Nov 4, 2026 (view filing)6:38 PM ET | Nov 2 | 2 days | Burnett PatrickEVP, Chief Medical Officer | SSale | −943 | $31.86 | −$30.0K | −0.8%116.6K after | |
| Nov 4, 2026 (view filing)6:38 PM ET | Nov 2 | 2 days | Watanabe Todd FranklinSee Remarks | SSale | −4.38K | $31.86 | −$139.5K | −0.6%712.8K after | |
| Oct 19, 2026 (view filing)4:49 PM ET | Oct 15 | 4 days | Welgus Howard G.Director | SSale | −4.73K | $26.93 | −$127.3K | −11.8%35.2K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:17 PM ET | Sep 16 | 2 days | Matsuda MasaruSee Remarks | SSale | −3.67K | $25.00 | −$91.9K | −3.2%112.5K after | 10b5-1 |
| Sep 17, 2026 (view filing)4:06 PM ET | Sep 15 | 2 days | Welgus Howard G.Director | SSale | −4.73K | $24.18 | −$114.4K | −11.7%35.8K after | 10b5-1 |
| Sep 10, 2026 (view filing)7:24 PM ET | Sep 8 | 2 days | Matsuda MasaruSee Remarks | SSale | −9.99K | $25.03 | −$250.0K | −7.9%116.2K after | 10b5-1 |
| Aug 28, 2026 (view filing)5:40 PM ET | Aug 27 | 1 day | Curran TerrieDirector | SSale | −38.2K | $25.03 | −$956.1K | −61.9%23.5K after | 2 lots |
| Aug 24, 2026 (view filing)4:19 PM ET | Aug 20 | 4 days | Curran TerrieDirector | SSale | −1.07K | $26.04 | −$27.9K | −4.4%23.5K after | |
| Aug 21, 2026 (view filing)4:08 PM ET | Aug 19 | 2 days | Burnett PatrickSee Remarks | SSale | −1.70K | $27.00 | −$45.8K | −1.4%117.6K after |
Top 10 13F holders, Q2 2026
See all 273 holdersThe largest institutional positions in Arcutis Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 12,437,000 | $326.1M | 6.85% | +110,000+0.9% | Added |
| BlackRock, Inc. | 10,545,466 | $276.5M | 0.00% | +1,345,055+14.6% | Added |
| Frazier Life Sciences Management, L.P. | 9,874,511 | $258.9M | 5.64% | 00.0% | Unchanged |
| Rubric Capital Management LP | 8,271,577 | $216.9M | 1.99% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 6,606,945 | $173.2M | 0.49% | +940,005+16.6% | Added |
| State Street Corp | 5,822,840 | $152.7M | 0.00% | −473,357−7.5% | Reduced |
| Vanguard Capital Management LLC | 4,988,756 | $130.8M | 0.00% | +117,220+2.4% | Added |
| Morgan Stanley | 4,451,014 | $116.7M | 0.01% | +232,083+5.5% | Added |
| Jennison Associates LLC | 4,219,058 | $110.6M | 0.07% | −761,712−15.3% | Reduced |
| D. E. Shaw & Co., Inc. | 3,949,609 | $103.6M | 0.06% | +1,453,387+58.2% | Added |
Holders of 5% or more of ARQT
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Arcutis Biotherapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 14.10%17.8M shares | – | Oct 22, 20243 filings | Oct 5, 2026 | SEC |
| Frazier Life Sciences VIII, L.P. | 13D/A | 7.50%8.94M shares | – | Feb 9, 20216 filings | Aug 20, 2025 | SEC |
| Rubric Capital Management LP | 13G/A | 6.75%8.27M shares | – | Feb 12, 20243 filings | Feb 13, 2026 | SEC |
| State Street Corp | 13G | 6.10%7.72M shares | +1.40 ppfrom 4.70% | Feb 8, 20235 filings | Nov 10, 2026 | SEC |
| Polar Capital Holdings Plc | 13G | 5.28%6.61M shares | +1.08 ppfrom 4.20% | Nov 16, 20235 filings | Aug 14, 2026 | SEC |
Politician trades
All politician trades in ARQT2 members of Congress reported 6 trades in Arcutis Biotherapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jun 8, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Apr 7, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Jan 12, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Sell (partial) | $1K-$15K |
| Oct 15, 2023 |  Josh Gottheimer House · NJ | Sell | $1K-$15K |
| May 19, 2023 | Josh Gottheimer House · NJ | Buy | $1K-$15K |
House · CA · Jun 8, 2026
Buy$1K-$15K
House · CA · Apr 7, 2026
Buy$1K-$15K
House · CA · Jan 12, 2026
Sell (partial)$1K-$15K
House · NJ · Oct 15, 2023
Sell$1K-$15K
House · NJ · May 19, 2023
Buy$1K-$15K